JP Morgan sees Apellis’ Syfovre as a potential $1.5B drug. Empaveli’s approval for C3G/IC-MPGN could drive stock growth with a U.S. launch in 2H 2025.
Latest Ratings for APLS
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 2022 | Goldman Sachs | Maintains | Buy | |
| Mar 2022 | Raymond James | Maintains | Strong Buy | |
| Jan 2022 | Raymond James | Maintains | Strong Buy |
